Johnson & Johnson’s newly formed consumer business has been targeted by claims its talcum powder can cause cancer, Jamie Smyth and Nicholas Megaw of The Financial Times reports. Kenvue has been named in seven talc lawsuits since the start of April, the Times says, according to regulatory filings and people familiar with the matter. Kenvue starts its IPO roadshow this week and will sell over-the-counter medicine and healthcare brands. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Alkermes arbitration award better than expected, says Mizuho
- Legend Biotech price target raised to $90 from $79 at BMO Capital
- Alkermes receives second interim award in Janssen arbitration
- Johnson & Johnson management to meet virtually with Oppenheimer
- Arcellx price target raised to $58 from $45 at Guggenheim